A review of treatment with mepolizumab, an anti–IL-5 mAb, in hypereosinophilic syndromes and asthma
- 1 April 2010
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 125 (4) , 803-813
- https://doi.org/10.1016/j.jaci.2009.11.048
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline (GSK 110184, MHE100185, MHE100901, SB-240563/001, SB-240563/006, SB-240563/036, SB-240563/046)
This publication has 66 references indexed in Scilit:
- FIP1L1-PDGFRα Imposes Eosinophil Lineage Commitment on Hematopoietic Stem/Progenitor CellsPublished by Elsevier ,2009
- Mepolizumab, a Humanized Monoclonal Antibody to IL-5, for Severe Eosinophilic Esophagitis in Adults: A Randomized, Placebo-Controlled Double-Blind TrialJournal of Allergy and Clinical Immunology, 2008
- A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophiliaCancer, 2007
- No Effect of Anti-Interleukin-5 Therapy (Mepolizumab) on the Atopy Patch Test in Atopic Dermatitis PatientsInternational Archives of Allergy and Immunology, 2006
- Hypereosinophilic Syndrome: Lymphoproliferative and Myeloproliferative VariantsSeminars in Respiratory and Critical Care Medicine, 2006
- The rise of the phoenix: the expanding role of the eosinophil in health and diseaseAllergy, 2004
- Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab)British Journal of Dermatology, 2004
- Abnormal Clones of T Cells Producing Interleukin-5 in Idiopathic EosinophiliaNew England Journal of Medicine, 1999
- Systemic corticosteroid therapy---side effects and their managementBritish Journal of Ophthalmology, 1998
- THE HYPEREOSINOPHILIC SYNDROMEMedicine, 1975